Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | BPTF | Q12830 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | BCHE | P06276 | 4/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24592550 | 0.84 | KDM4E (0.32) | MAPK1KDM4E | |
| SCHEMBL14668170 | 0.80 | ACHE (0.37) | ACHEMEN1KMT2AMAPK1BPTF | |
| SCHEMBL337198 | 0.75 | ACHE (0.48) | ACHEMEN1KMT2AMAPK1BPTF | |
| SCHEMBL10533578 | 0.74 | KDM4E (0.33) | MAPK1KDM4EL3MBTL1 | |
| SCHEMBL18029792 | 0.71 | — | — | |
| SCHEMBL21586570 | 0.71 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL22795578 | 0.71 | — | — | |
| SCHEMBL21646536 | 0.71 | HAVCR2 (0.31) | — | |
| SCHEMBL19475249 | 0.71 | ACHE (0.44) | ACHEMEN1KMT2AMAPK1BPTF | |
| SCHEMBL21962356 | 0.71 | ACHE (0.44) | ACHEMEN1KMT2AMAPK1BPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109126-A1 | DIHYDRO-OXAZOL DERIVATIVE COMPOUNDS | AC IMMUNE SA (CH) | 2025-04-03 | — | — | US | disclosed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| EP-4452972-A1 | DIHYDRO-OXAZOL DERIVATIVE COMPOUNDS | AC Immune SA (CH) | 2024-10-30 | — | — | EP | disclosed |
| CN-113582889-B | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2024-09-20 | — | — | CN | disclosed |
| CN-118541366-A | Dihydrooxazole derivative compound | AC免疫有限公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-3416948-B1 | INDACENE BEARING SULFONYLUREAS AS ANTI-INFLAMMATORY AGENTS | UNIV QUEENSLAND (AU) | 2024-07-24 | — | — | EP | disclosed |
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-01-02 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| EP-3578547-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2019-12-11 | — | — | EP | disclosed |
| US-20190337965-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2019-11-07 | — | — | US | disclosed |
| WO-2019043610-A1 | NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2019-03-07 | — | — | WO | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| EP-3259253-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2017-12-27 | — | — | EP | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | ACHE 4661/4885MEN1 4202/4885KMT2A 4317/4885 |
| US-20190337965-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | ACHE 4373/4885MEN1 4064/4885KMT2A 4240/4885 |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | ACHE 4110/4885MEN1 3639/4885KMT2A 4072/4885 |
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | NLRP3, NOD1, PYCARD | ACHE 3968/4885MEN1 2219/4885KMT2A 3753/4885 |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | ACHE 4110/4885MEN1 3639/4885KMT2A 4072/4885 |
| US-20250109126-A1 | DIHYDRO-OXAZOL DERIVATIVE COMPOUNDS | NLRP3, NLRP1, NOD1 | ACHE 4834/4885MEN1 4414/4885KMT2A 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.